Lasa Supergenerics Ltd. (IN:LASA)
:LASA
Top Page
Lasa Supergenerics Ltd.
(LASA)
Select Model
Select Model
Rating:45Neutral
Price Target:
₹6.00
▼(-47.04% Downside)
Action:ReiteratedDate:03/28/26
The score is driven primarily by weak financial performance (declining revenue, negative margins, and negative cash flows). Technicals reinforce the risk with a clear downtrend and bearish momentum, while valuation offers limited support because earnings are negative and there is no dividend yield.
Positive Factors
B2B API manufacturing model
Lasa's core business is manufacturing APIs for other drugmakers, a durable B2B model with recurring order potential and long-term supply contracts. This specialization supports steady industrial demand and stable unit-level revenues versus consumer-facing cyclicality over months.
Negative Factors
Sharp revenue decline
Near-50% revenue contraction is a structural strain: loss of scale increases per-unit costs, weakens negotiating power with suppliers/customers, and makes it harder to cover fixed costs. Restoring volumes will take sustained commercial recovery and may require investment or pricing shifts.
Read all positive and negative factors
Positive Factors
Negative Factors
B2B API manufacturing model
Lasa's core business is manufacturing APIs for other drugmakers, a durable B2B model with recurring order potential and long-term supply contracts. This specialization supports steady industrial demand and stable unit-level revenues versus consumer-facing cyclicality over months.
Read all positive factors
Lasa Supergenerics Ltd. (LASA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹344.70M
Dividend YieldN/A
Average Volume (3M)39.13K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth-20.40%
EPS Growth-59.20%
CountryIN
Employees77
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,101,240
10 Day Avg. Volume9,122
30 Day Avg. Volume39,131
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.08
Price to Sales (P/S)0.63
P/FCF Ratio-32.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lasa Supergenerics Ltd. Business Overview & Revenue Model
Company Description
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products primarily in India. It offers veterinary and other API products, anthelmintic products, animal feed ingredients, and reagents fo...
How the Company Makes Money
LASA primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) and related chemical products. Its core revenue stream is B2B sales of bulk drugs/APIs to pharmaceutical companies that formulate and market finished-...
Lasa Supergenerics Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 952.90M | 1.42B | 1.04B | 1.30B | 1.37B | 2.02B |
| Gross Profit | 212.29M | 362.61M | 286.95M | -111.88M | 427.84M | 886.86M |
| EBITDA | -319.14M | -43.91M | -64.66M | -246.85M | 84.12M | 469.92M |
| Net Income | -361.69M | -147.57M | -217.31M | -386.21M | -53.31M | 227.78M |
Balance Sheet | ||||||
| Total Assets | 716.03M | 1.02B | 1.51B | 1.64B | 2.09B | 2.08B |
| Cash, Cash Equivalents and Short-Term Investments | 6.96M | 7.90M | 14.96M | 21.78M | 172.17M | 44.00M |
| Total Debt | 73.38M | 21.27M | 220.76M | 217.70M | 201.71M | 194.63M |
| Total Liabilities | 152.61M | 178.19M | 541.92M | 455.69M | 512.87M | 489.43M |
| Stockholders Equity | 563.42M | 837.13M | 966.76M | 1.18B | 1.58B | 1.59B |
Cash Flow | ||||||
| Free Cash Flow | -899.00K | -28.24M | 21.39M | -173.00M | 92.12M | 347.24M |
| Operating Cash Flow | 2.59M | -28.24M | 21.39M | -173.00M | 92.12M | 413.10M |
| Investing Cash Flow | -1.00M | 81.52M | -3.98M | 111.95M | -29.12M | -35.97M |
| Financing Cash Flow | -1.46M | -56.62M | -19.32M | -41.61M | -403.00K | -364.43M |
Lasa Supergenerics Ltd. Technical Analysis
Negative
11.33
Price Trends
8.06
Negative
9.02
Negative
10.00
Negative
Market Momentum
-0.57
Positive
39.47
Neutral
28.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LASA, the sentiment is Negative. The current price of 11.33 is above the 20-day moving average (MA) of 7.09, above the 50-day MA of 8.06, and above the 200-day MA of 10.00, indicating a bearish trend. The MACD of -0.57 indicates Positive momentum. The RSI at 39.47 is Neutral, neither overbought nor oversold. The STOCH value of 28.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LASA.
Lasa Supergenerics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ₹1.14B | 16.40 | ― | 1.62% | -9.07% | 5.36% | |
56 Neutral | ₹527.11M | 172.45 | ― | ― | 36.76% | 433.63% | |
53 Neutral | ₹1.27B | 111.96 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹1.69B | 84.53 | ― | ― | -17.47% | -50.07% | |
45 Neutral | ₹344.70M | -4.63 | ― | ― | -20.40% | -59.20% |
* Healthcare Sector Average
IN:LASA
Lasa Supergenerics Ltd.
6.88
-11.00
-61.52%
IN:AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd.
59.60
12.88
27.57%
IN:BALAXI
Balaxi Pharmaceuticals Limited
22.94
-43.62
-65.53%
IN:BALPHARMA
Bal Pharma Limited
71.60
-38.63
-35.04%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
32.39
-10.33
-24.18%
Lasa Supergenerics Ltd. Corporate Events
Exchange Seeks Clarification From Lasa Supergenerics on Q3 FY2025 Results
Mar 11, 2026
The stock exchange has requested clarification from Lasa Supergenerics Ltd. regarding its financial results for the quarter ended Dec. 31, 2025, under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements. The company has yet t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.